125 related articles for article (PubMed ID: 8115838)
1. [Immune response to anti-meningococcal vaccines].
Milagres LG; Melles CE
Rev Saude Publica; 1993 Jun; 27(3):221-6. PubMed ID: 8115838
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
3. [Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
Vescia N; Mastroeni I; Pompa MG; Signorelli C; Fara GM
Ann Ig; 1989; 1(6):1293-8. PubMed ID: 2484465
[TBL] [Abstract][Full Text] [Related]
4. [Anti-meningococcal vaccines].
Taha MK; Alonso JM
Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536
[TBL] [Abstract][Full Text] [Related]
5. [Immune response to meningococci].
Flaegstad T
Tidsskr Nor Laegeforen; 1989 Jan; 109(1):33-6. PubMed ID: 2492123
[TBL] [Abstract][Full Text] [Related]
6. The implications of vaccines for prevention of bacterial meningitis.
Riordan A
Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
[TBL] [Abstract][Full Text] [Related]
7. Serogroup B meningococcal vaccines.
Zimmer SM; Stephens DS
Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal vaccines.
Bethell D; Pollard AJ
Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
[TBL] [Abstract][Full Text] [Related]
9. Development of new vaccines against meningococcal disease.
Bröker M
Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960
[TBL] [Abstract][Full Text] [Related]
10. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
Wu C
Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
[No Abstract] [Full Text] [Related]
11. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.
Milagres LG; Cristina M; Brandileone MC; Sacchi CT; Vieira VS; Zanella RC; Frasch CE
FEMS Immunol Med Microbiol; 1996 Jan; 13(1):9-17. PubMed ID: 8821393
[TBL] [Abstract][Full Text] [Related]
12. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
Xie O; Pollard AJ; Mueller JE; Norheim G
Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
[TBL] [Abstract][Full Text] [Related]
13. Vaccine against meningococcal group B disease.
Lifely MR; Moreno C
Lancet; 1986 Jan; 1(8474):214-5. PubMed ID: 2868239
[No Abstract] [Full Text] [Related]
14. [The outlook for the development of a vesicular meningococcal serogroup B vaccine].
Del'vig AA; Semenov BF
Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):91-6. PubMed ID: 9532701
[No Abstract] [Full Text] [Related]
15. Neisseria meningitidis serogroup B vaccine development.
Caesar NM; Myers KA; Fan X
Microb Pathog; 2013 Apr; 57():33-40. PubMed ID: 23416222
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of BC meningococcal vaccine in Brazil.
Nishioka S
Int J Epidemiol; 1996 Oct; 25(5):1102-3. PubMed ID: 8921501
[No Abstract] [Full Text] [Related]
18. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan.
Chiou CS; Liao JC; Liao TL; Li CC; Chou CY; Chang HL; Yao SM; Lee YS
BMC Infect Dis; 2006 Feb; 6():25. PubMed ID: 16478548
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
Milagres LG; Gorla MC; Rebelo MC; Barroso DE
FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
[TBL] [Abstract][Full Text] [Related]
20. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
Jennings HJ
Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
